ID: ALA3235085

Max Phase: Preclinical

Molecular Formula: C18H14F3N5O3S

Molecular Weight: 437.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCNC(=O)Nc1cc(-c2nc(C(F)(F)F)cs2)c(-c2cncc(C(=O)O)c2)cn1

Standard InChI:  InChI=1S/C18H14F3N5O3S/c1-2-23-17(29)26-14-4-11(15-25-13(8-30-15)18(19,20)21)12(7-24-14)9-3-10(16(27)28)6-22-5-9/h3-8H,2H2,1H3,(H,27,28)(H2,23,24,26,29)

Standard InChI Key:  GLNFAHNABSNEAM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 437.40

Molecular Weight (Monoisotopic): 437.0769

AlogP: 4.13

#Rotatable Bonds: 5

Polar Surface Area: 117.10

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.91

CX Basic pKa: 2.59

CX LogP: 2.52

CX LogD: -0.43

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.55

Np Likeness Score: -1.54

References

1. Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE..  (2013)  Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,  56  (21): [PMID:24098982] [10.1021/jm401208b]

2. Ho SY, Wang W, Ng FM, Wong YX, Poh ZY, Tan SWE, Ang SH, Liew SS, Joyner Wong YS, Tan Y, Poulsen A, Pendharkar V, Sangthongpitag K, Manchester J, Basarab G, Hill J, Keller TH, Cherian J..  (2018)  Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.,  157  [PMID:30125722] [10.1016/j.ejmech.2018.08.025]

Source

Source(1):

• Scientific Literature